| Abstrakt: |
Researchers at Peking Union Medical College Hospital in Beijing, China have conducted a study on the clinical characteristics of anti-neuronal antibody positive paraneoplastic neurological syndrome (PNS) related to immune checkpoint inhibitors (ICI). The study included five patients with anti-neuronal antibody positive ICI-PNS, with tumor types including small cell lung cancer, malignant melanoma, Hodgkin lymphoma, and cervical cancer. The patients presented with high-risk neurologic phenotypes of PNS, such as limbic encephalitis and rapidly progressive cerebellar syndrome. After discontinuation of ICIs and treatment with glucocorticoids and intravenous immunoglobulin (IVIg), the patients' neurological symptoms improved. The study concludes that high/intermediate-risk anti-neuronal antibodies are diagnostic markers of ICI-PNS and that evaluation of clinical phenotypes and grading are important for immunotherapy. [Extracted from the article] |
